4 Results for "

Jurkat T-ALL cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Jurkat T-ALL cells" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-14174
CAS No.: 677772-84-8
Purity:  99.51%
Target:  

γ-secretase

Research Areas:  

Neurological Disease Cancer

MRK-560, a chemical probe, is an orally active, brain barrier-penetrated γ-Secretase inhibitor, reducing Aβ peptide in rat brain and cerebrospinal fluid. MRK-560 decreases mutant NOTCH1 processing by selectively inhibiting PSEN1. MRK-560 can be used in studies of Alzheimer's disease and T-cell acute lymphoblastic leukaemia (T-ALL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153244
CAS No.: 2088715-91-5
Purity:  98.07%
Target:  

CDK

Research Areas:  

Cancer

MFH290 is an orally active, selective covalent CDK12/CDK13 inhibitor, with an IC50 of 25 nM against human CDK12 and 49 nM against human CDK13. MFH290 reduces the phosphorylation level of CTD-RNAPII-Ser2, downregulates genes related to DNA damage response (DDR), and inhibits transcription factors regulated by super-enhancers. MFH290 can be used in research related to various cancers including leukemia .
loading...
    loading...
Cat. No.: HY-176244
CAS No.: 1351116-34-1
Research Areas:  

Cancer

KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC50 of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 + T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .
loading...
    loading...
Cat. No.: HY-181653
CAS No.: 3120650-15-6
PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a Kd value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research .
loading...
    loading...